FDA 483 response

The observation is issued. Can your organization show the decision behind it?

A credible response depends on more than corrective action. It depends on whether the evidence, judgment, risk, and authorization behind the cited decision can withstand scrutiny.

Plan your 15 business days See a completed Inspection Response Record →

Completed example · No account required · Questions?

Before you respond

Can you answer this from the record today?

Think of the decision the observation is testing. Answer four questions about it, as an investigator would.

Can you show what was known when the decision was made?

Can you show why this path was chosen over the alternatives?

Can you show what risk was accepted and what was left open?

Can you show who authorized it, and on what basis?

Your 483 · Your 15 business days

Which decision is your observation really testing?

The observation cites

The decision under reviewClosing CAPA as effective
By

Set the issue date

Name the decision and pull the record as it stood at the time.

In your IRR: Decision
By

Set the issue date

The effectiveness data you had at closure, kept apart from anything gathered after the 483.

In your IRR: Evidence · Judgment
By

Set the issue date

Who signed it effective, against which criteria, and what was left open.

In your IRR: Risk · Authorization

Response target: set the issue date

Build the record for this decision · $497

Suggested internal milestones, not FDA dates. The 15-business-day count skips weekends and U.S. federal holidays; confirm the date against FDA’s guidance and with your regulatory counsel.

The record leadership uses

Turn a fragmented investigation trail into a reviewable decision record.

Illustrative example: CAPA-2025-0118. Select a row.

Inspection Response RecordIllustrative example

The Inspection Response Record is built for one completed consequential GMP decision. It organizes the evidence, judgment, risk, and authorization into a reviewer-ready record without replacing the company’s authoritative QMS documentation or its FDA response process.

FDA 483 response timing

When should an FDA 483 response be prepared?

FDA states that a Form FDA 483 is not a final agency determination. For drug CGMP inspections, establishments are not required to respond, but FDA recommends that those choosing to respond submit within 15 business days after the FDA 483 is issued. A response received within that period is generally reviewed before FDA determines whether to pursue subsequent action.

What if the observations are too complex to resolve in 15 business days?

If complex observations cannot be fully addressed within the period, FDA’s March 2026 draft guidance recommends submitting a CAPA plan and proposed timeframe for substantive responses within 15 business days.

What should be established before the response is approved?

Identify the decision being tested, confirm the contemporaneous evidence, separate later remediation from the original record, make residual risk explicit, and confirm accountable authorization.

Regulatory source: FDA, Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection (Draft Guidance, March 2026; nonbinding recommendations).

Before you explain the observation, make the decision behind it visible.

Review the decision record first. Then let your response team, quality leaders, and counsel proceed from the same record.

See a completed Inspection Response Record Request a 483 decision briefing

ComplianceWorxs does not draft or submit a Form 483 response, provide legal advice, or communicate with FDA on a customer’s behalf.

When the FDA inspector asks who authorized this and why, ComplianceWorxs is the record that answers.